Compare PDLB & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PDLB | RGNX |
|---|---|---|
| Founded | 1960 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 401.0M | 418.1M |
| IPO Year | 2021 | 2015 |
| Metric | PDLB | RGNX |
|---|---|---|
| Price | $17.68 | $10.15 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 8 |
| Target Price | N/A | ★ $28.75 |
| AVG Volume (30 Days) | 40.4K | ★ 495.7K |
| Earning Date | 04-24-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 160.87 | 18.08 |
| EPS | ★ 1.20 | N/A |
| Revenue | N/A | ★ $10,393,000.00 |
| Revenue This Year | N/A | $51.21 |
| Revenue Next Year | N/A | $19.08 |
| P/E Ratio | $14.74 | ★ N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $12.85 | $6.89 |
| 52 Week High | $18.05 | $16.19 |
| Indicator | PDLB | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 58.19 | 65.17 |
| Support Level | $15.84 | $7.76 |
| Resistance Level | $18.02 | $10.37 |
| Average True Range (ATR) | 0.36 | 0.54 |
| MACD | -0.03 | 0.10 |
| Stochastic Oscillator | 69.52 | 99.53 |
Ponce Financial Group Inc, is a United States-based holding company. Its business consists of taking deposits from the general public and investing those deposits, together with funds generated from operations, in mortgage loans, consisting of one-to-four-family residential, multi-family residential, non-residential property and construction and land, and, to a lesser extent, business, and consumer loans. The company also invests in securities, which consists of securities issued by the U.S. Government and federal agencies and mortgage-backed securities issued by the United States government-sponsored enterprises. Some of the products and services include checking solutions, online and mobile banking, merchant credit card services, and others.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.